| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3269537 | HPB | 2013 | 5 Pages |
Abstract
Treatment with gemcitabine plus i.v. nâ3FA may reduce concentrations of CAF which may be associated with an improved outcome. Baseline ILâ6 and â8 may be surrogate markers for outcome in patients with APC treated with this regimen.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Ali Arshad, Wen Y. Chung, William Steward, Matthew S. Metcalfe, Ashley R. Dennison,